News
Nexelis Wins ViE Award for Best Central/Specialty Laboratory
Nexelis, a portfolio company of Ampersand Capital Partners and a leading provider of advanced assay and biomarker development and laboratory testing services in immunology, specifically infectious diseases, immuno-oncology, and metabolic diseases fields, announced it has won Best Central/Specialty Laboratory in Terrapinn’s Vaccine Industry Excellence (ViE) awards on May, 5 2021 at the World Vaccine Congress.
Nexelis bested an elite field of established industry names — including Icon, Covance, and Quest Diagnostics — for the award.
“The World Vaccine Congress and Terrapin contacts hundreds of companies to determine the ViE finalists in each category in order to determine which are most outstanding in supporting vaccine research,” said Nexelis CEO Benoit Bouche. “We were pleased to join our nominated peers, but to win is wonderful regonition of the hard work of the entire Nexelis team and of our customers, who allowed us to partner with them to develop these critical vaccine therapies.”
Nexelis VP Vaccine Sciences Luc Gagnon recently presented to the World Vaccine Congress on Transformative Public/Private Partnership: Action with Urgency to Accelerate SARS-CoV-2 Vaccine Candidates’ Development alongside Valentina Bernasconi of CEPI. The two companies partnered to rapidly support the global response to the COVID-19 pandemic, with Nexelis as CEPI’s referral lab for humoral and cellular testing for SARS-CoV-2 and its variants, evaluating vaccines in antivirals in all preclinical and clinical phases. To receive a copy of the presentation slide deck, please contact Britney Bartel at britney.bartel@nexelis.com or Greg Kulnis at greg.kulnis@nexelis.com.
About Nexelis
With an unrivaled expertise in immunology, five operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection stage to late clinical stage, Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields. Our versatile team of scientists, working with our state-of-the-art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene, and cell therapy products. Additional information about Nexelis is available at www.nexelis.com.